Results 11 to 20 of about 328,224 (217)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors

Frontiers in Immunology, 2023
PurposeTo investigate the incidence of immune-related adverse events (irAEs) of immune checkpoint inhibitor (ICI) therapy and to report the clinical features, management, and outcomes of ophthalmic irAEs.MethodsWe retrospectively reviewed the medical ...
Linyang Gan, Huan Chen, Xiaowei Liu, Li Zhang   +3 more
doaj   +1 more source

Immune-related adverse events of immune checkpoint inhibitors: a review

Frontiers in Immunology, 2023
Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved.
Qinan Yin, Qinan Yin, Liuyun Wu, Liuyun Wu, Lizhu Han, Lizhu Han, Xingyue Zheng, Xingyue Zheng, Rongsheng Tong, Rongsheng Tong, Lian Li, Lian Li, Lan Bai, Lan Bai, Yuan Bian, Yuan Bian   +15 more
doaj   +1 more source

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs

OncoImmunology, 2023
Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of melanoma patients. However, ICIs can cause an overactivation of the immune system followed by diverse immunological side effects known as immune-related adverse events (irAE)
Alisa Lepper, Rebekka Bitsch, Feyza Gül Özbay Kurt, Ihor Arkhypov, Samantha Lasser, Jochen Utikal, Viktor Umansky   +6 more
doaj   +1 more source

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia

Frontiers in Pharmacology, 2019
Immune-related hematological adverse events are amongst the rare but potentially life-threatening complications of immune checkpoint inhibitors.
Roser Calvo
doaj   +1 more source

Clinical assessment of immune-related adverse events

Therapeutic Advances in Medical Oncology, 2018
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance.
Aaron Sosa, Esther Lopez Cadena, Cristina Simon Olive, Niki Karachaliou, Rafael Rosell   +4 more
doaj   +1 more source

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors

Journal of Experimental & Clinical Cancer Research, 2020
The enthusiasm for immune checkpoint inhibitors (ICIs), an efficient tumor treatment model different from traditional treatment, is based on their unprecedented antitumor effect, but the occurrence of immune-related adverse events (irAEs) is an obstacle ...
Xiao-Hui Jia, Lu-Ying Geng, Pan-Pan Jiang, Hong Xu, Ke-Jun Nan, Yu Yao, Li-Li Jiang, Hong Sun, Tian-Jie Qin, Hui Guo   +9 more
doaj   +1 more source

Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study

Frontiers in Oncology, 2022
BackgroundImmune checkpoint inhibitors (ICIs) are associated with different immune-related adverse events (irAEs), but there is limited evidence regarding the association between urinary incontinence and ICIs.MethodsWe described the case of a patient ...
Yizhang Hu, Wenchao Lu, Borui Tang, Zhixia Zhao, Zhuoling An   +4 more
doaj   +1 more source

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system

Thoracic Cancer, 2020
Immunotherapy for malignant tumors is a hot spot in current research and the treatment of cancer. The activation of programmed cell death receptor‐1 (PD‐1) and cytotoxic T lymphocyte‐associated antigen 4 (CTLA)‐4 relevant signaling pathway can inhibit ...
Yue Li, Xiaohui Kang, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiaoyan Si, Li Zhang, Xiaowei Liu, Jiaming Qian, Li Zhang   +10 more
doaj   +1 more source

Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis

Frontiers in Immunology, 2022
BackgroundNeoadjuvant immunotherapy has preliminarily been effective in multiple resectable cancers. However, its safety is still largely unknown.MethodsA systematic literature search was conducted in PubMed, Embase, Web of Science, and Cochrane Library ...
Jiawei Xu, Yongfeng Wu, Yuedan Xu, Yuan Qiu, Xiaobo Li, Yumeng Song, Ling Zhang   +6 more
doaj   +1 more source

Temporary Severe Neutropenia during Administration of Atezolizumab: A Novel Case Report

Case Reports in Oncology, 2023
Here, we describe a case of temporary severe neutropenia after atezolizumab monotherapy and its treatment course. Atezolizumab monotherapy was introduced as a 6th-line treatment for a man in his late 60s, who was diagnosed with stage Ⅳ lung ...
Ryota Kanno, Yoshitaka Saito, Yoh Takekuma, Hajime Asahina, Mitsuru Sugawara   +4 more
doaj   +1 more source